 Isoniazid
"Isoniazid" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.
| Descriptor ID |
D007538
|
| MeSH Number(s) |
D02.442.436 D03.066.349.410 D03.383.725.394.582
|
| Concept/Terms |
Isoniazid- Isoniazid
- Isonicotinic Acid Hydrazide
- Hydrazide, Isonicotinic Acid
Phthivazide- Phthivazide
- Phthivazid
- Isonicotinic Acid Vanillylidenehydrazide
- Acid Vanillylidenehydrazide, Isonicotinic
- Vanillylidenehydrazide, Isonicotinic Acid
- Ftivazide
|
Below are MeSH descriptors whose meaning is more general than "Isoniazid".
Below are MeSH descriptors whose meaning is more specific than "Isoniazid".
This graph shows the total number of publications written about "Isoniazid" by people in this website by year, and whether "Isoniazid" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 1 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Isoniazid" by people in Profiles.
-
Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of Latent Tuberculosis Infection: An Updated Network Meta-analysis. Ann Intern Med. 2017 Aug 15; 167(4):248-255.
-
Stagg HR, Harris RJ, Hatherell HA, Obach D, Zhao H, Tsuchiya N, Kranzer K, Nikolayevskyy V, Kim J, Lipman MC, Abubakar I. What are the most efficacious treatment regimens for isoniazid-resistant tuberculosis? A systematic review and network meta-analysis. Thorax. 2016 Oct; 71(10):940-9.
-
Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, Den Boon S, Borroto Gutierrez SM, Bruchfeld J, Burhan E, Cavalcante S, Cedillos R, Chaisson R, Chee CB, Chesire L, Corbett E, Dara M, Denholm J, de Vries G, Falzon D, Ford N, Gale-Rowe M, Gilpin C, Girardi E, Go UY, Govindasamy D, D Grant A, Grzemska M, Harris R, Horsburgh CR, Ismayilov A, Jaramillo E, Kik S, Kranzer K, Lienhardt C, LoBue P, Lönnroth K, Marks G, Menzies D, Migliori GB, Mosca D, Mukadi YD, Mwinga A, Nelson L, Nishikiori N, Oordt-Speets A, Rangaka MX, Reis A, Rotz L, Sandgren A, Sañé Schepisi M, Schünemann HJ, Sharma SK, Sotgiu G, Stagg HR, Sterling TR, Tayeb T, Uplekar M, van der Werf MJ, Vandevelde W, van Kessel F, van't Hoog A, Varma JK, Vezhnina N, Voniatis C, Vonk Noordegraaf-Schouten M, Weil D, Weyer K, Wilkinson RJ, Yoshiyama T, Zellweger JP, Raviglione M. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015 Dec; 46(6):1563-76.
-
Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: a network meta-analysis. Ann Intern Med. 2014 Sep 16; 161(6):419-28.
-
Kremer L, Dover LG, Morbidoni HR, Vilchèze C, Maughan WN, Baulard A, Tu SC, Honoré N, Deretic V, Sacchettini JC, Locht C, Jacobs WR, Besra GS. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J Biol Chem. 2003 Jun 06; 278(23):20547-54.
-
Wei CJ, Lei B, Musser JM, Tu SC. Isoniazid activation defects in recombinant Mycobacterium tuberculosis catalase-peroxidase (KatG) mutants evident in InhA inhibitor production. Antimicrob Agents Chemother. 2003 Feb; 47(2):670-5.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|